HT Vet expands AI scanner to flag specific canine tumors
Bottom line
HT Vet’s Vista iQ scanner is moving beyond general cancer screening and into tumor-specific classification for canine skin and subcutaneous masses. New peer-reviewed research, highlighted this week by Today’s Veterinary Business, found the AI-powered heat-diffusion imaging system could identify lipomas and mast cell tumors within defined risk bands, while maintaining strong rule-out performance for malignancy. In the new study, the mast cell tumor classifier showed 90.9% sensitivity and 97.8% specificity, and the lipoma classifier showed 86.4% sensitivity and 100% specificity in the evaluated subset. The company says that could help clinics tailor next steps earlier, including recognizing when a mass may warrant mast cell tumor precautions before aspiration. (todaysveterinarybusiness.com)
Why it matters: For veterinary teams, the practical shift is from a tool used mainly to support “rule out malignancy” decisions toward one that may also help guide case-specific workflows. That’s especially relevant for mast cell tumors, which can resemble benign lipomas on physical exam. Earlier HT Vista research in 664 masses reported 85% sensitivity and 97% negative predictive value overall, but also showed false negatives were concentrated in mast cell tumors, underscoring why a more targeted classifier matters. If the newer model holds up in broader real-world use, it could improve triage, support conversations with pet parents who hesitate on FNA, and help clinics decide when to premedicate or escalate diagnostics sooner. (frontiersin.org)
What to watch: Whether HT Vet publishes external validation data and how quickly clinics incorporate the tumor-specific outputs into standard mass-workup protocols. (pubmed.ncbi.nlm.nih.gov)
Key facts
- Product
- HT Vet’s Vista iQ scanner
- Use
- Tumor-specific classification for canine skin and subcutaneous masses
- Tumor types
- Lipomas and mast cell tumors
- Mast cell tumor classifier
- 90.9% sensitivity, 97.8% specificity
- Lipoma classifier
- 86.4% sensitivity, 100% specificity
- Earlier study
- 664 masses; 85% sensitivity, 67% specificity, 97% negative predictive value
- Key limitation
- False negatives were all mast cell tumors
- Clinical note
- May help clinics recognize when a mass warrants mast cell tumor precautions before aspiration
HT Vet’s Vista iQ scanner is taking a notable step from broad canine cancer screening toward tumor-specific identification. According to new peer-reviewed research and a fresh industry write-up from Today’s Veterinary Business, the company’s AI-powered heat-diffusion imaging platform can now flag two common and clinically important mass types in dogs, lipomas and mast cell tumors, rather than only estimating whether a lump is likely benign or malignant. (todaysveterinarybusiness.com)
That’s an important evolution for a device that entered the market as a non-invasive point-of-care tool for evaluating dermal and subcutaneous masses. Earlier coverage in 2023 described HT Vista as a scanner intended to help rule out cancer in suspicious canine lumps, with immediate exam-room results on a 1-to-10 scale. A 2023 Frontiers in Veterinary Science study of 664 masses reported overall sensitivity of 85%, specificity of 67%, and a 97% negative predictive value, supporting its use as a screening tool, but it also showed that the false-negative cases were all mast cell tumors. (todaysveterinarybusiness.com)
The new paper, indexed on PubMed last month, focused specifically on building and internally validating tumor-specific AI classifiers for mast cell tumors and lipomas. In the evaluated subset, the mast cell tumor classifier achieved 90.9% sensitivity and 97.8% specificity, while the lipoma classifier achieved 86.4% sensitivity and 100% specificity; all 38 masses flagged as lipoma in that analysis were lipomas. HT Vet has also described these features as part of its updated platform, saying the subclassifiers are designed to flag lipomas in very low-risk cases and mast cell tumors in very high-risk cases. (pubmed.ncbi.nlm.nih.gov)
The company’s framing is that this moves the system from a “rule out” screen toward something closer to a “rule in” aid for selected tumors. In its own materials, HT Vet says the mast cell tumor output may help clinicians adjust protocols before aspiration, while the lipoma output could reduce unnecessary invasive procedures in clearly benign-appearing cases. That positioning aligns with the clinical reality that mast cell tumors can be deceptively similar to lipomas on palpation and visual exam, a point highlighted in prior AAHA coverage of the technology. (ht-vet.com)
Industry reaction so far appears to center on workflow and earlier intervention. In HT Vet’s January 20, 2026 launch announcement for Vista iQ, oncologist Craig Clifford said delayed workups can change the trajectory of mast cell tumor and soft tissue sarcoma cases, and practice owner Michael Morris said the scanner has helped his team discuss findings in the exam room and make next-step decisions faster. Those comments come from company-linked materials, so they should be read as supportive perspectives rather than independent validation, but they help explain how HT Vet is positioning the scanner in practice operations as well as diagnostics. (prnewswire.com)
Why it matters: For veterinary professionals, the key issue isn’t whether AI replaces cytology or histopathology, it doesn’t, but whether it improves the front end of mass evaluation. Most canine lumps still go untested, according to HT Vet’s launch materials, and that leaves room for missed or delayed diagnoses. A non-invasive scan that increases confidence in which masses need immediate aspiration, biopsy, referral, or pre-aspiration antihistamine planning could improve compliance and shorten time to action. At the same time, the newest tumor-specific data are internally validated and company-funded, so clinicians will likely want to see broader external validation before treating the subclassifier outputs as anything more than an adjunct to standard diagnostics. (prnewswire.com)
There’s also a business and workflow angle. HT Vet says Vista iQ can be operated by technicians in about 40 seconds and has been distributed through major veterinary channels in the U.S. The company reported more than 35,000 scans performed in the U.S. since commercialization in 2023, suggesting a growing installed base that could generate additional real-world evidence on performance, false positives, false negatives, and how often scanner results actually change case management. (prnewswire.com)
What to watch: The next milestones are likely independent validation, publication of fuller study details beyond the abstract, and evidence that the tumor-specific outputs improve clinical decision-making without increasing overconfidence in borderline cases. For now, Vista iQ’s new classifiers look like a meaningful refinement of an existing screening platform, especially for mast cell tumors, but not a replacement for aspirates, pathology, or clinical judgment. (pubmed.ncbi.nlm.nih.gov)